|Title:||2017 Taiwan lipid guidelines for high risk patients||Authors:||Li Y.-H.
The Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients
|Issue Date:||2017||Journal Volume:||116||Journal Issue:||4||Start page/Pages:||217-248||Source:||Journal of the Formosan Medical Association||Abstract:||
In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of coronary artery disease in Taiwan. We recognized that lipid control is especially important in patients with existed atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), ischemic stroke and peripheral arterial disease (PAD). Because the risk of ASCVD is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and familial hypercholesterolemia (FH), lipid control is also necessary in these patients. Lifestyle modification is the first step to control lipid. Weight reduction, regular physical exercise and limitation of alcohol intake all reduce triglyceride (TG) levels. Lipid-lowering drugs include HMG-CoA reductase inhibitors (statins), cholesterol absorption inhibitors (ezetimibe), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, nicotinic acids (niacin), fibric acids derivatives (fibrates), and long-chain omega-3 fatty acids. Statin is usually the first line therapy. Combination therapy with statin and other lipid-lowering agents may be considered in some clinical settings. For patients with acute coronary syndrome (ACS) and stable CAD, LDL-C < 70 mg/dL is the major target. A lower target of LDL-C <55 mg/dL can be considered in ACS patients with DM. After treating LDL-C to target, non-HDL-C can be considered as a secondary target for patients with TG ? 200 mg/dL. The suggested non-HDL-C target is < 100 mg/dL in ACS and CAD patients. For patients with ischemic stroke or transient ischemic attack presumed to be of atherosclerotic origin, statin therapy is beneficial and LDL-C < 100 mg/dL is the suggested target. For patients with symptomatic carotid stenosis or intracranial arterial stenosis, in addition to antiplatelets and blood pressure control, LDL-C should be lowered to < 100 mg/dL. Statin is necessary for DM patients with CV disease and the LDL-C target is < 70 mg/dL. For diabetic patients who are ? 40 years of age, or who are < 40 years of age but have additional CV risk factors, the LDL-C target should be < 100 mg/dL. After achieving LDL-C target, combination of other lipid-lowering agents with statin is reasonable to attain TG < 150 mg/dL and HDL-C >40 in men and >50 mg/dL in women in DM. LDL-C increased CV risk in patients with CKD. In adults with glomerular filtration rate (GFR) < 60 mL/min/1.73m2 without chronic dialysis (CKD stage 3–5), statin therapy should be initiated if LDL-C ? 100 mg/dL. Ezetimibe can be added to statin to consolidate the CV protection in CKD patients. Mutations in LDL receptor, apolipoprotein B and PCSK9 genes are the common causes of FH. Diagnosis of FH usually depends on family history, clinical history of premature CAD, physical findings of xanthoma or corneal arcus and high levels of LDL-C. In addition to conventional lipid lowering therapies, adjunctive treatment with mipomersen, lomitapide, or PCSK9 inhibitors become necessary to further reduce LDL-C in patients with FH. Overall, these recommendations are to help the health care professionals in Taiwan to treat hyperlipidemia with current scientific evidences. We hope the prescription rate of lipid lowering drugs and control rate of hyperlipidemia in high risk patients could be increased by implementation of the clinical guidelines. The major purpose is to improve clinical outcomes of these high risk patients through the control of hyperlipidemia. ? 2016
|ISSN:||9296646||DOI:||10.1016/j.jfma.2016.11.013||metadata.dc.subject.other:||apolipoprotein B; cholesterol; cholesterol ester transfer protein inhibitor; ezetimibe; fibric acid derivative; fish oil; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; lipid; lomitapide; low density lipoprotein cholesterol; low density lipoprotein receptor; mipomersen; nicotinic acid; omega 3 fatty acid; proprotein convertase 9; triacylglycerol; hypocholesterolemic agent; low density lipoprotein cholesterol; acute coronary syndrome; alcohol consumption; brain ischemia; carotid artery obstruction; cerebrovascular accident; cholesterol blood level; chronic kidney failure; combination drug therapy; coronary artery atherosclerosis; coronary artery disease; diabetes mellitus; diabetic patient; dietary supplement; dyslipidemia; exercise; follow up; genetics; glomerulus filtration rate; high risk patient; human; hyperlipidemia; lifestyle modification; medical literature; occlusive cerebrovascular disease; peripheral occlusive artery disease; practice guideline; pregnancy; Review; risk factor; Taiwan; transient ischemic attack; weight reduction; atherosclerosis; blood; complication; healthy diet; Hyperlipidemias; lifestyle; practice guideline; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Healthy Diet; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Practice Guidelines as Topic; Risk Factors; Taiwan
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.